Navigation Links
New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine

Paul Coussens, a professor of animal science and microbiology and molecular genetics, and his colleagues from Michigan State University found that a new cell// line has the ability and potential for growing flu virus.

This is good news because it would result in the production of new human flu vaccines which is cheaper and produced in a shorter period of time.

He identified the new cell line while working on the Marek's disease which is a common chicken disease. This technique is very useful and is not time consuming when compared to the earlier procedure in which the virus strains were grown in fertilized chicken eggs. HepaLife Technologies Inc., a biotechnology company based in Vancouver, has licensed the technology from MSU and plans to produce cell culture-based flu vaccine. ‘We want to proceed as quickly as possible,’ said Harmel Rayat, president of HepaLife. ‘There's no time to waste. Sooner or later the avian flu virus will be in North America. It's not if, it's when.’

‘The recent highly virulent avian flu cases in Asia and fears about a pandemic have highlighted the problems with traditional influenza vaccine production methods, particularly the length of time to produce a new vaccine and the amount of vaccine that can be produced on short notice,’ said Coussens, who also is the director of the MSU Center for Animal Functional Genomics. Building on work done by graduate student Amin Abujoub and assistant professor David Reilly, Coussens and his collaborators found the cell line would grow almost every type of flu virus: avian, swine, equine and human.

In cell culture-based vaccine production, scientists infect cells with flu strains. Then they grow the virus in large vats or bioreactors. The virus is killed and purified to make the vaccine. Growing virus in cell culture could dramatically speed up vaccine production. For the past 50 years, flu vaccines have been made by injecting 11-day-old fertilized chicken eggs with a flu virus strain. The virus grows in the eggs and is then killed and purified to make the vaccine. Each egg is injected with only one virus strain (a typical flu vaccine contains three strains) and produces enough virus for one or two doses. This means that huge numbers of fertilized chicken eggs are needed – 270 million or more – to produce a sufficient vaccine supply for the United States.

The process is time consuming and inflexible because vaccine makers have to order eggs months ahead of time. If there are any problems with the eggs, such as infection by another virus, the entire lot of flu vaccine is lost. Plus, anyone with an egg allergy can't have the vaccine. ‘By growing cell culture-based flu virus, the cost and the time needed to produce the vaccine will be much lower,’ Coussens said. ‘We'll also be able to produce much more vaccine in a smaller space. And the virus that is grown is more pure. People with allergies to eggs are likely to benefit the most because they'll be able to have flu shots without the threat of allergic complications.’

Source: urekalert
'"/>




Related medicine news :

1. Stem Cell Bank In UK Would Require 150 Embryo-Derived Stem Cell Lines
2. Increased Childhood Leukemia Risk If House Is Near Power Lines
3. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
4. Tea Found To Boost Insulin Production And Prevent Cataract
5. Conroy’s May Not Be Permitted To Resume Production Soo
6. Massive Production Of Bird Flu Vaccine To Be Initiated In China
7. Chugai Pharmaceutical To Initiate Domestic Production Of Bird Flu Vaccine
8. Coca Cola To Enhance Production Of Diet Coke
9. Natco Pharma Commences Production At Dehradun Unit
10. ABCB6 Is Key to Production of Heme in Hemoglobin
11. Drug Boosts Platelet Production, Reversing Immune Thrombocytopenic Purpura
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... ... 05, 2016 , ... Successful recruitment and retention efforts, new ... initiatives have all marked the last 12 months at Roswell Park Cancer Institute ... nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology: